Oxford Biomedica plc

Oxford Biomedica plc is a leading gene and cell therapy company, specializing in the development and manufacturing of lentiviral vectors which are crucial for gene therapy treatments. These technologies are fundamental in the treatment of various diseases including cancer, ophthalmology, and rare genetic disorders. The company operates primarily in the biotechnology and life sciences sector, playing a pivotal role in the advancement of personalized medicine. Oxford Biomedica partners with a variety of biopharmaceutical companies to provide groundbreaking therapies, often serving as a contract development and manufacturing organization (CDMO). This enables them to support the entire lifecycle of gene and cell therapy products, from discovery through commercialization. Based in the United Kingdom, Oxford Biomedica has solidified its position in the global market through innovation and strategic partnerships, contributing significantly to the evolution of genetic medicine and the broader biopharmaceutical industry.